Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B.
QSAR
aurora kinase B
pharmacophore modeling
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Nov 2022
22 Nov 2022
Historique:
received:
19
09
2022
revised:
01
11
2022
accepted:
11
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Aurora kinase B (AKB) is a crucial signaling kinase with an important role in cell division. Therefore, inhibition of AKB is an attractive approach to the treatment of cancer. In the present work, extensive quantitative structure-activity relationships (QSAR) analysis has been performed using a set of 561 structurally diverse aurora kinase B inhibitors. The Organization for Economic Cooperation and Development (OECD) guidelines were used to develop a QSAR model that has high statistical performance (R
Identifiants
pubmed: 36498857
pii: ijms232314527
doi: 10.3390/ijms232314527
pmc: PMC9739353
pii:
doi:
Substances chimiques
Aurora Kinase B
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia
ID : research group number RG-21-09-77
Références
J Chem Inf Model. 2014 Jan 27;54(1):1-4
pubmed: 24251851
Methods Mol Biol. 2018;1800:141-169
pubmed: 29934891
J Chem Inf Model. 2012 Aug 27;52(8):2044-58
pubmed: 22721530
Eur J Med Chem. 2017 Nov 10;140:1-19
pubmed: 28918096
J Chem Inf Comput Sci. 2003 Mar-Apr;43(2):579-86
pubmed: 12653524
J Chem Inf Model. 2018 Jan 22;58(1):36-47
pubmed: 29202231
Cancer Metastasis Rev. 2009 Jun;28(1-2):185-95
pubmed: 19189202
Mol Inform. 2019 Jan;38(1-2):e1800029
pubmed: 30142701
Clin Exp Pharmacol Physiol. 2016 Jun;43(6):585-601
pubmed: 26999067
J Comput Aided Mol Des. 1990 Mar;4(1):1-105
pubmed: 2197373
Curr Med Chem. 2009;16(16):1949-63
pubmed: 19519375
J Mol Model. 2011 May;17(5):1191-205
pubmed: 20697761
J Chem Inf Model. 2010 Jul 26;50(7):1189-204
pubmed: 20572635
Expert Opin Ther Pat. 2021 Jul;31(7):625-644
pubmed: 33573401
J Enzyme Inhib Med Chem. 2022 Dec;37(1):109-117
pubmed: 34894976
Cell Div. 2018 Sep 19;13:7
pubmed: 30250494
J Med Chem. 2009 May 14;52(9):2629-51
pubmed: 19320489
Pharmaceuticals (Basel). 2022 Jul 05;15(7):
pubmed: 35890133
J Comput Chem. 2011 Aug;32(11):2386-96
pubmed: 21541967
Mol Inform. 2014 Apr;33(4):311-4
pubmed: 27485777
J Chem Inf Model. 2011 Sep 26;51(9):2320-35
pubmed: 21800825
J Med Chem. 2012 Sep 13;55(17):7841-8
pubmed: 22920039
Pharmaceuticals (Basel). 2022 Jun 14;15(6):
pubmed: 35745664
Acta Crystallogr F Struct Biol Commun. 2014 Mar;70(Pt 3):294-8
pubmed: 24598913
Acta Pharmacol Sin. 2010 Feb;31(2):244-58
pubmed: 20139908
Pharmaceuticals (Basel). 2022 Mar 01;15(3):
pubmed: 35337101
Methods Mol Biol. 2013;930:499-526
pubmed: 23086855
Anticancer Drugs. 2010 Apr;21(4):339-50
pubmed: 20016367
Mol Cancer. 2021 Jan 15;20(1):15
pubmed: 33451333
Sci Rep. 2021 Sep 21;11(1):18707
pubmed: 34548506
J Med Chem. 2014 Jun 26;57(12):4977-5010
pubmed: 24351051
Invest New Drugs. 2012 Dec;30(6):2411-32
pubmed: 22350019
J Cheminform. 2011 Oct 07;3:33
pubmed: 21982300
Curr Pharm Des. 2007;13(34):3494-504
pubmed: 18220786
J Chem Inf Model. 2012 Oct 22;52(10):2570-8
pubmed: 23030316
J Chem Inf Model. 2010 Dec 27;50(12):2094-111
pubmed: 21033656
Front Oncol. 2015 Dec 21;5:278
pubmed: 26734566
Mol Pharm. 2011 Apr 4;8(2):600-8
pubmed: 21370915
J Comput Chem. 2011 May;32(7):1466-74
pubmed: 21425294
J Chem Inf Model. 2016 Feb 22;56(2):269-74
pubmed: 26754147
Arch Pharm Res. 2015 Sep;38(9):1686-701
pubmed: 26208641
Curr Pharm Des. 2016;22(5):572-81
pubmed: 26601966
Mol Inform. 2012 Dec;31(11-12):817-35
pubmed: 27476736